Kenyans can now provide detailed first-hand information about their experiences with pharmaceutical products via a mobile App.
This follows the launch of the Mobile Pharmacovigilance Electronic Reporting System (mPVERS), a platform developed by the Pharmacy and Poisons Board (PPB) that will now help in monitoring of quality, safety and efficacy of health products and technologies in Kenya.
Through the mobile based tool, Kenyans will be able to timely report if they encounter adverse events from vaccines, over the counter medicines, herbal medicines, or suspected poor quality health products.
Speaking during the launch, Health Chief Administrative Secretary, Dr.Rashid Aman, said the move will empower the consumers and improve their involvement in the management of their own health.
This he said includes reports of adverse events for “over the counter” (OTC) medicines, herbal medicines, vaccines and reports on suspected poor quality health products.
Adding that consumer reporting is therefore a useful tool in empowering the consumers and improving their involvement in the management of their own health.
” In this regard, the PPB through immense support from the USAID Medicines, Technologies and Pharmaceutical Services (MTaPS) Program has developed a mPvERS system. This is a mobile based solution that provides a reporting platform in form of a mobile application for both android and iPhone operating system and an Unstructured Supplementary Service Data (USSD) solution,” he said.
This mobile solution is in form of a mobile application for both android and iOS and an Unstructured Supplementary Service Data (USSD) solution. pic.twitter.com/XeUU0r93CO
— Pharmacy and Poisons (@ppbkenya) April 13, 2022
The CAS said the solution is developed to supplement the existing national reporting system PvERS II, launched in March 2021 to increase and improve consumer reporting and AEFI reporting.
He noted that the Ministry of Health through Pharmacy and Poisons Board is committed to providing Kenyans with safe, quality and efficacious medical products and health technologies.
” We are looking forward to great outputs from this system. I call upon all of us to support this initiative as we strive to ensure that the public is using quality, safe and efficacious health products and technologies,” said the CAS